Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome (2020)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1016/j.cyto.2020.155192
- Subjects: CARDIOPATIAS CONGÊNITAS; HIPERTENSÃO PULMONAR; QUIMIOCINAS; SÍNDROME DE DOWN
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SOUZA, Maria Francilene S et al. Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome. Cytokine, v. 134, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.cyto.2020.155192. Acesso em: 26 dez. 2025. -
APA
Souza, M. F. S., Carvalho, E. S., Maeda, N. Y., Thomaz, A. M., Zorzanelli, L., Castro, C. R., et al. (2020). Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome. Cytokine, 134. doi:10.1016/j.cyto.2020.155192 -
NLM
Souza MFS, Carvalho ES, Maeda NY, Thomaz AM, Zorzanelli L, Castro CR, Pereira J, Lopes AA. Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome [Internet]. Cytokine. 2020 ; 134[citado 2025 dez. 26 ] Available from: https://doi.org/10.1016/j.cyto.2020.155192 -
Vancouver
Souza MFS, Carvalho ES, Maeda NY, Thomaz AM, Zorzanelli L, Castro CR, Pereira J, Lopes AA. Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome [Internet]. Cytokine. 2020 ; 134[citado 2025 dez. 26 ] Available from: https://doi.org/10.1016/j.cyto.2020.155192 - Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
Informações sobre o DOI: 10.1016/j.cyto.2020.155192 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
